Bain Capital Life Sciences Fund II, L.P.
CIK 1773187 · last filed 2025-02-21
Bain Capital Life Sciences Fund II, L.P. is a corporate insider who has filed 4 SEC Form 4 insider transactions across 1 company since 2025. The most recent filing, for NAMS, was dated Dec 2, 2025. Across all open-market trades the lifetime net is +$40.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $36.9M across reported positions. The firm reports its address in Boston, MA. 7 SEC filings were submitted jointly with BCIP Life Sciences Associates, LP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$36.90M
1
4
$40.30M
Filer Profile
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SLDB | 10%+ Owner | 5,034,582 | $7.33 | $36.90M | $40.30M | 1 | 2025-02-21 |
Recent Filings
4 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-02 | NAMS | Notice (144) | −267,429 | -$10.25M | EDGAR |
| 2025-07-24 | NUVL | Notice (144) | −1,286,344 | -$105.58M | EDGAR |
| 2025-02-21 | SLDB | Buy (P) | +10,000,000 | $40.30M | EDGAR |
| 2024-12-11 | NUVL | Notice (144) | −1,114,286 | -$104.31M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.